摘要
目的:探讨吉西他滨联合顺铂治疗老年晚期非小细胞肺癌的临床疗效。方法:回顾性分析我院近年来收治的80例老年晚期非小细胞肺癌患者的临床资料。结果:80例老年晚期非小细胞肺癌患者,中位生存时间38.6周,1年生存率为43.75%(35/80)。其中,鳞癌44例,客观有效率为43.18%,疾病控制率为77.27%。腺癌36例,客观有效率为38.89%,疾病控制率为75.0%。两种不同病理类型的晚期非小细胞肺癌患者,临床疗效经统计学分析,P>0.05,无明显差异性。白细胞下降Ⅲ～Ⅳ级发生率31.25%,居毒副反应的首位,但所有毒副反应经对症处理患者均可耐受,无化疗相关死亡病例。结论:吉西他滨联合顺铂治疗老年晚期非小细胞肺癌的临床疗效确切,毒副反应可以耐受,值得临床推广使用。
Objective：Gemcitabine and cisplatin treatment of advanced non-small cell lung cancer.Methods：Retrospective analysis of hospital in recent years,80 cases of elderly patients with advanced non-small cell lung cancer patients with clinical data.Results：80 cases of elderly patients with advanced non-small cell lung cancer patients,the median survival time was 38.6 weeks,1 year survival rate was 43.75%（35/80）.Among them,44 cases of squamous cell carcinoma,objective response rate was 43.18%,disease control rate was 77.27%.36 cases of adenocarcinoma,objective response rate was 38.89%,disease control rate was 75.0%.Two different pathological types of advanced non small cell lung cancer patients,clinical efficacy by statistical analysis,P 0.05,no significant difference.Leukopenia grade Ⅲ ～ Ⅳ the incidence of 31.25%,the highest toxicity of the first,but the toxic side effects can be tolerated by symptomatic treatment of patients with no chemotherapy-related deaths.Conclusions：Gemcitabine and cisplatin treatment of advanced non-small cell lung cancer is effective,toxicity is tolerable for clinical use.
出处
《航空航天医药》
2010年第8期1447-1448,共2页
Aerospace Medicine
关键词
吉西他滨
顺铂
非小细胞肺癌
Gemcitabine
Cisplatin
Non-small cell lung cancer
